To view or add a comment, sign in Figure 2 from this recent genetic cardiomyopathy paper is wild Patients with type 2 diabetes who carry a pathogenic cardiomyopathy variant had a 16% rate of heart failure hospitalization at 4 years on placebo, approx 5 higher than noncarriers
The most notable is A
48 Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ
Together these observations suggest that not just any degeneration of myelin, but a specific modification of its constituents is required to elicit a secondary adaptive immune response
In the past, theyve been prescribed primarily to treat people with type 2 diabetes, but theyre now being used by a wider range of people for general weight loss, but also migraine and hormone management in some cases
That investigation has now occurred (at least in preliminary form), and the human results are more reassuring than the animal data suggested